What podcasts say about Uttam Dey
Every statement, with the speaker, the exact quote and the moment it was said.
What Uttam Dey has said on podcasts
9 statements · 8 positive · 1 negative
AI inference will begin producing meaningful monetization over the next one to two years.
“I'm quite optimistic about where we're going to go, you know, over the next one to two years, as we see inference switching gears into the real monetization”
Open the episode · S&P hits all-time highs, AI trade does all the workListen at 15:14
A less communicative Chairman Walsh could increase uncertainty around interest-rate expectations.
“we could suddenly see a, you know, Chairman Walsh who is trying not to give as much information and just let the market dictate their own forces and their own conclusions around the interest rate outlook.”
Open the episode · S&P hits all-time highs, AI trade does all the workListen at 16:37
Ongoing AI M&A signals that the AI business outlook remains strong.
“if M&A is happening. That's one sign of AI business that the outlook for AI is still strong.”
Open the episode · S&P hits all-time highs, AI trade does all the workListen at 17:47
Amazon’s reported Descartes AI acquisition would benefit Amazon, AWS, and AI competitiveness.
“I think this is just a great plus for Amazon and for AWS and for AI.”
Open the episode · S&P hits all-time highs, AI trade does all the workListen at 20:07
Marvell is entering a faster growth phase driven by optical networking.
“Marvel's, I think, going to switch into this new mode of acceleration.”
Open the episode · S&P hits all-time highs, AI trade does all the workListen at 30:33
Marvell’s revenue growth is expected to accelerate from 47% this year to about 67% next year.
“And they expect 47% of revenue growth this year. That accelerates to about, I think, 67% next year.”
Open the episode · S&P hits all-time highs, AI trade does all the workListen at 31:27
AMD’s growth could accelerate to approximately 75%.
“We're talking about probably an acceleration to 75% growth.”
Open the episode · S&P hits all-time highs, AI trade does all the workListen at 36:51
AI can provide its greatest benefit in early preclinical drug-testing stages.
“it's the AI, if AI has to actually provide a benefit, it's the first one or two stages in preclinical AI testing, preclinical drug testing stages. where they can provide maximum value and benefit.”
Open the episode · S&P hits all-time highs, AI trade does all the workListen at 42:35
Successful AI drug-development applications could drive substantial monetization in 2027.
“if that happens, 2027 is going to be such a great year for just, you know, delivering the kind of monetization that everyone was asking for.”
Open the episode · S&P hits all-time highs, AI trade does all the workListen at 43:18
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.